Ipratropium bromide

What ipratropium bromide is and how it works

Ipratropium bromide is an inhaled anticholinergic (antimuscarinic) bronchodilator used as maintenance treatment for bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. In some markets, it is also used together with an inhaled beta2-agonist bronchodilator for reversible airways obstruction in asthma. (1)

Ipratropium bromide does not carry a boxed warning, but it does carry a genuine warning that it can cause paradoxical bronchospasm (sudden worsening of breathing) that can be life-threatening, and anticholinergic-class precautions around eye pressure (narrow-angle glaucoma) and urinary retention. It works locally in the airways and is not intended to relieve a sudden asthma or COPD attack on its own -- follow your prescribed regimen and never exceed the maximum stated number of inhalations in 24 hours without your clinician's guidance.

Mechanism of action: how ipratropium bromide works

Ipratropium bromide is a quaternary ammonium anticholinergic (antimuscarinic) compound that blocks acetylcholine's effect at muscarinic receptors in bronchial smooth muscle, producing bronchodilation; its action is predominantly local to the lung, with limited systemic absorption and a terminal elimination half-life of approximately 1.6 hours per New Zealand regulator sources reviewed. (1) (6)

What ipratropium bromide is used for

Before taking ipratropium bromide

Do not take / not appropriate for

• Do not use ipratropium bromide if you are allergic to it, to atropine or its derivatives, or to any ingredient in the specific product. (all countries) (1) (2)

Tell your clinician about

• Any history of narrow-angle glaucoma or increased eye pressure.
• Any history of prostatic hyperplasia (enlarged prostate) or difficulty urinating (bladder-neck obstruction).
• Whether your breathing suddenly worsens after using this inhaler, since this can indicate paradoxical bronchospasm.
• All other inhalers and medicines you use, especially other bronchodilators.

How to take ipratropium bromide

• Ipratropium bromide is taken by inhalation, using a metered-dose inhaler or a nebuliser solution, exactly as directed by your clinician.
• It is intended for regular, scheduled maintenance use, not as a fast-relief rescue inhaler for a sudden attack -- follow your prescribed regimen.
• Take care not to spray or nebulise the mist directly into your eyes, since this can cause eye pain, blurred vision, or worsen narrow-angle glaucoma.

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3) (4) (5) (6)

Missed dose

Contact your clinician or pharmacist for guidance if you miss a scheduled dose -- do not double up or change your schedule yourself.

Overdose

Seek urgent medical attention for a suspected overdose. Because ipratropium bromide acts mainly locally in the airways, systemic overdose effects are uncommon, but anticholinergic symptoms (such as dry mouth, blurred vision, or difficulty urinating) could occur with excessive use -- report these promptly. (6)

Side effects

Side effects and their urgency vary; report severe, persistent, or concerning symptoms.

Serious warnings

Interactions

• Using ipratropium bromide together with other anticholinergic (antimuscarinic) medicines may increase anticholinergic side effects such as dry mouth, blurred vision, or urinary difficulty -- discuss all your medicines with your clinician or pharmacist. (2)

Pregnancy, breastfeeding, kidney/liver function, age

Monitoring

Before starting

• History of narrow-angle glaucoma
• History of prostatic hyperplasia or urinary retention
• Correct inhaler/nebuliser technique to avoid eye contact

During treatment

• Watch for and report any sudden worsening of breathing after a dose (possible paradoxical bronchospasm).
• Watch for and report eye pain, vision changes, or new urinary difficulty.

Storage

Store the inhaler or nebuliser solution as directed on the product label, typically at room temperature, protected from heat and direct sunlight, out of reach of children.

Frequently asked questions

References

1. ATROVENT HFA (ipratropium bromide) inhalation aerosol -- full prescribing informationU.S. Food and Drug Administration / DailyMed (NIH), full prescribing information, Boehringer Ingelheim · United States · accessed 2026-07-30 · source 1
2. Atrovent Inhaler CFC-Free (ipratropium bromide) -- Summary of Product Characteristicselectronic medicines compendium (emc), United Kingdom -- Boehringer Ingelheim Limited · United Kingdom · accessed 2026-07-30 · source 2
3. ATROVENT Inhaler CFC-Free -- HPRA product licence/SmPCHealth Products Regulatory Authority (HPRA), Ireland -- a European Union member-state regulator · European Union (Ireland) · accessed 2026-07-30 · source 3
4. ATROVENT HFA (ipratropium bromide) -- Product MonographHealth Canada product monograph, Boehringer Ingelheim (Canada) Ltd. · Canada · accessed 2026-07-30 · source 4
5. ATROVENT ipratropium bromide -- multiple ARTG entries (e.g. 39953, 91129, 17909, 58203)Therapeutic Goods Administration (TGA), Australia · Australia · accessed 2026-07-30 · source 5
6. Atrovent HFA -- New Zealand Data Sheet (v04)Medsafe (New Zealand Medicines and Medical Devices Safety Authority) · New Zealand · accessed 2026-07-30 · source 6

Brand names by country

Single-ingredient ipratropium bromide names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.

Priority countries